The last two weeks saw market clearances granted in Europe for AI-based software focused on remote patient monitoring, prostate oncology and real-time guidance of coronary stenting.
Company announcements:
Biobeat’s AI-powered remote patient monitoring platform receives a full CE mark (May 4)
Exini Diagnostics receives CE mark clearance for AI-powered quantitative assessment of prostate-specific membrane antigen (May 3)
Abbott’s new coronary imaging platform powered by artificial intelligence launches in Europe (April 26)
Dave P. has worked in journalism, marketing and public relations for more than 30 years, frequently concentrating on hospitals, healthcare technology and Catholic communications. He has also specialized in fundraising communications, ghostwriting for CEOs of local, national and global charities, nonprofits and foundations.